KLRK1 and neoplasm: The expression of peripheral NK cell-activated receptors (CD94/NKG2C, NKG2D, and CD16) and inhibitory receptors (NKG2A) from BC patients was reduced, highlighting the importance of NK cells as suitable targets for effective antitumor responses in the BC immunosuppressive tumor microenvironment33.